Advertisement

Atrial Fibrillation in the Elderly

  • Stefano FumagalliEmail author
  • Debbie Gabbai
  • Luigi Padeletti
  • Harry J. Crijns
  • Gregory Y. H. Lip
Chapter

Abstract

Atrial fibrillation (AF) is the most frequent sustained arrhythmia in the elderly. AF is often associated with (and aggravates the clinical course of) several age-related disorders, such as chronic heart failure, non-ST-elevation myocardial infarction, cerebrovascular disease, chronic obstructive pulmonary disease, pneumonia, and urinary infections. Older patients can develop the most severe complications of AF, such as stroke and dementia. Despite existing evidence, oral anticoagulation is still underused in the elderly. A rate-control strategy is frequently adopted. In conclusion, AF in elderly patients is common and often represents a marker of multiple comorbidities and frailty. Management should aim at reducing symptoms and improving health-related quality of life and survival.

References

  1. 1.
    Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133:e38–360.CrossRefPubMedGoogle Scholar
  2. 2.
    Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013;34:2746–51.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129:837–47.CrossRefPubMedGoogle Scholar
  4. 4.
    Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114:119–25.CrossRefPubMedGoogle Scholar
  5. 5.
    Collerton J, Davies K, Jagger C, et al. Health and disease in 85 year olds: baseline findings from the Newcastle 85+ cohort study. BMJ. 2009;339:b4904. doi: 10.1136/bmj.b4904.:b4904.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Pan NH, Tsao HM, Chang NC, Chen YJ, Chen SA. Aging dilates atrium and pulmonary veins: implications for the genesis of atrial fibrillation. Chest. 2008;133:190–6.CrossRefPubMedGoogle Scholar
  7. 7.
    McManus DD, Xanthakis V, Sullivan LM, et al. Longitudinal tracking of left atrial diameter over the adult life course: clinical correlates in the community. Circulation. 2010;121:667–74.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Gramley F, Lorenzen J, Knackstedt C, et al. Age-related atrial fibrosis. Age (Dordr). 2009;31:27–38.CrossRefGoogle Scholar
  9. 9.
    Burkauskiene A, Mackiewicz Z, Virtanen I, Konttinen YT. Age-related changes in myocardial nerve and collagen networks of the auricle of the right atrium. Acta Cardiol. 2006;61:513–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Asirvatham SJ, Gard JJ. Wrinkles in the atrium: age, atrial fibrillation, or something else. J Am Coll Cardiol. 2011;58:2233–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Bejot Y, Ben Salem D, Osseby GV, et al. Epidemiology of ischemic stroke from atrial fibrillation in Dijon, France, from 1985 to 2006. Neurology. 2009;72:346–53.CrossRefPubMedGoogle Scholar
  12. 12.
    Yiin GS, Howard DP, Paul NL, et al. Age-specific incidence, outcome, cost, and projected future burden of atrial fibrillation-related embolic vascular events: a population-based study. Circulation. 2014;130:1236–44.CrossRefPubMedGoogle Scholar
  13. 13.
    Leyden JM, Kleinig TJ, Newbury J, et al. Adelaide stroke incidence study: declining stroke rates but many preventable cardioembolic strokes. Stroke. 2013;44:1226–31.CrossRefPubMedGoogle Scholar
  14. 14.
    Cotter PE, Martin PJ, Ring L, Warburton EA, Belham M, Pugh PJ. Incidence of atrial fibrillation detected by implantable loop recorders in unexplained stroke. Neurology. 2013;80:1546–50.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Marfella R, Sasso FC, Siniscalchi M, et al. Brief episodes of silent atrial fibrillation predict clinical vascular brain disease in type 2 diabetic patients. J Am Coll Cardiol. 2013;62:525–30.CrossRefPubMedGoogle Scholar
  16. 16.
    Lamassa M, Di Carlo A, Pracucci G, et al. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke. 2001;32:392–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263–72.CrossRefPubMedGoogle Scholar
  18. 18.
    Bekwelem W, Connolly SJ, Halperin JL, et al. Extracranial systemic embolic events in patients with nonvalvular atrial fibrillation: incidence, risk factors, and outcomes. Circulation. 2015;132:796–803.CrossRefPubMedGoogle Scholar
  19. 19.
    Alonso A, Lopez FL, Matsushita K, et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011;123:2946–53.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Go AS, Fang MC, Udaltsova N, et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation. 2009;119:1363–9.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367:625–35.CrossRefPubMedGoogle Scholar
  22. 22.
    Piccini JP, Stevens SR, Chang Y, et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation. 2013;127:224–32.CrossRefPubMedGoogle Scholar
  23. 23.
    Boriani G, Savelieva I, Dan GA, et al. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace. 2015;17:1169–96.CrossRefPubMedGoogle Scholar
  24. 24.
    Jover E, Marin F, Roldan V, Montoro-Garcia S, Valdes M, Lip GY. Atherosclerosis and thromboembolic risk in atrial fibrillation: focus on peripheral vascular disease. Ann Med. 2013;45:274–90.CrossRefPubMedGoogle Scholar
  25. 25.
    Anandasundaram B, Lane DA, Apostolakis S, Lip GY. The impact of atherosclerotic vascular disease in predicting a stroke, thromboembolism and mortality in atrial fibrillation patients: a systematic review. J Thromb Haemost. 2013;11:975–87.CrossRefPubMedGoogle Scholar
  26. 26.
    Mitchell GF, Vasan RS, Keyes MJ, et al. Pulse pressure and risk of new-onset atrial fibrillation. JAMA. 2007;297:709–15.CrossRefPubMedGoogle Scholar
  27. 27.
    Violi F, Davi G, Hiatt W, et al. Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation: implications for risk and therapy. J Am Coll Cardiol. 2013;62:2255–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Violi F, Davi G, Proietti M, et al. Ankle-Brachial Index and cardiovascular events in atrial fibrillation. The ARAPACIS Study. Thromb Haemost. 2016;115:856–63.CrossRefPubMedGoogle Scholar
  29. 29.
    Fumagalli S, Gabbai D, Nreu B, et al. Age, left atrial dimension and arterial stiffness after external cardioversion of atrial fibrillation. A vascular component in arrhythmia maintenance? Results from a preliminary study. Aging Clin Exp Res. 2014;26:327–30.CrossRefPubMedGoogle Scholar
  30. 30.
    Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263–71.CrossRefPubMedGoogle Scholar
  31. 31.
    Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke. 1997;28:316–21.CrossRefPubMedGoogle Scholar
  32. 32.
    Miyasaka Y, Barnes ME, Petersen RC, et al. Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a community-based cohort. Eur Heart J. 2007;28:1962–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Thacker EL, McKnight B, Psaty BM, et al. Atrial fibrillation and cognitive decline: a longitudinal cohort study. Neurology. 2013;81:119–25.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Dublin S, Anderson ML, Haneuse SJ, et al. Atrial fibrillation and risk of dementia: a prospective cohort study. J Am Geriatr Soc. 2011;59:1369–75.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Kwok CS, Loke YK, Hale R, Potter JF, Myint PK. Atrial fibrillation and incidence of dementia: a systematic review and meta-analysis. Neurology. 2011;76:914–22.CrossRefPubMedGoogle Scholar
  36. 36.
    Udompanich S, Lip GY, Apostolakis S, Lane DA. Atrial fibrillation as a risk factor for cognitive impairment: a semi-systematic review. QJM. 2013;106:795–802.CrossRefPubMedGoogle Scholar
  37. 37.
    Swardfager W, Black SE. Coronary artery calcification: a canary in the cognitive coalmine. J Am Coll Cardiol. 2016;67:1023–6.CrossRefPubMedGoogle Scholar
  38. 38.
    Leonard BE. Inflammation, depression and dementia: are they connected? Neurochem Res. 2007;32:1749–56.CrossRefPubMedGoogle Scholar
  39. 39.
    Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–67.CrossRefPubMedGoogle Scholar
  40. 40.
    Sellers MB, Newby LK. Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients. Am Heart J. 2011;161:241–6.CrossRefPubMedGoogle Scholar
  41. 41.
    Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370:493–503.CrossRefPubMedGoogle Scholar
  42. 42.
    Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009;151:297–305.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Lip GY, Clementy N, Pericart L, Banerjee A, Fauchier L. Stroke and major bleeding risk in elderly patients aged >/=75 years with atrial fibrillation: the Loire Valley atrial fibrillation project. Stroke. 2015;46:143–50.CrossRefPubMedGoogle Scholar
  44. 44.
    Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation. 2012;125:2298–307.CrossRefPubMedGoogle Scholar
  45. 45.
    Poli D, Antonucci E, Testa S, Tosetto A, Ageno W, Palareti G. Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. Circulation. 2011;124:824–9.CrossRefPubMedGoogle Scholar
  46. 46.
    Fumagalli S, Nieuwlaat R, Tarantini F, et al. Characteristics, management and prognosis of elderly patients in the Euro Heart Survey on atrial fibrillation. Aging Clin Exp Res. 2012;24:517–23.PubMedGoogle Scholar
  47. 47.
    Fumagalli S, Said S, Laroche C, et al. Age-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: The EORP-AF general pilot registry (EUR Observational Research Programme-Atrial Fibrillation). JACC Clin Electrophysiol. 2015;1:326–34.CrossRefGoogle Scholar
  48. 48.
    Flaker GC, Pogue J, Yusuf S, et al. Cognitive function and anticoagulation control in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010;3:277–83.CrossRefPubMedGoogle Scholar
  49. 49.
    Jacobs V, Woller SC, Stevens S, et al. Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementia. Heart Rhythm. 2014;11:2206–13.CrossRefPubMedGoogle Scholar
  50. 50.
    Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.CrossRefPubMedGoogle Scholar
  51. 51.
    Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123:2363–72.CrossRefPubMedGoogle Scholar
  52. 52.
    Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.CrossRefPubMedGoogle Scholar
  53. 53.
    Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.CrossRefPubMedGoogle Scholar
  54. 54.
    Deedwania PC. New oral anticoagulants in elderly patients with atrial fibrillation. Am J Med. 2013;126:289–96.CrossRefPubMedGoogle Scholar
  55. 55.
    Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.CrossRefPubMedGoogle Scholar
  56. 56.
    Halvorsen S, Atar D, Yang H, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014;35:1864–72.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol. 2012;110:453–60.CrossRefPubMedGoogle Scholar
  58. 58.
    Sardar P, Chatterjee S, Chaudhari S, Lip GY. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc. 2014;62:857–64.CrossRefPubMedGoogle Scholar
  59. 59.
    Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–47.CrossRefPubMedGoogle Scholar
  60. 60.
    Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093–100.CrossRefPubMedGoogle Scholar
  61. 61.
    Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17:1467–507.CrossRefPubMedGoogle Scholar
  62. 62.
    Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32:2387–94.CrossRefPubMedGoogle Scholar
  63. 63.
    Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33:2821–30.CrossRefPubMedGoogle Scholar
  64. 64.
    Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131:157–64.CrossRefPubMedGoogle Scholar
  65. 65.
    Fumagalli S, Cardini F, Roberts AT, et al. Psychological effects of treatment with new oral anticoagulants in elderly patients with atrial fibrillation: a preliminary report. Aging Clin Exp Res. 2015;27:99–102.CrossRefPubMedGoogle Scholar
  66. 66.
    Shariff N, Desai RV, Patel K, et al. Rate-control versus rhythm-control strategies and outcomes in septuagenarians with atrial fibrillation. Am J Med. 2013;126:887–93.CrossRefPubMedGoogle Scholar
  67. 67.
    Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation. 2004;109:1509–13.CrossRefPubMedGoogle Scholar
  68. 68.
    Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 2000;342:913–20.CrossRefPubMedGoogle Scholar
  69. 69.
    Flaker G, Lopes RD, Hylek E, et al. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. J Am Coll Cardiol. 2014;64:1541–50.CrossRefPubMedGoogle Scholar
  70. 70.
    Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Mahe I, Bergmann JF. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med. 2006;166:719–28.CrossRefPubMedGoogle Scholar
  71. 71.
    Chao TF, Liu CJ, Tuan TC, et al. Rate-control treatment and mortality in atrial fibrillation. Circulation. 2015;132:1604–12.CrossRefPubMedGoogle Scholar
  72. 72.
    Kotecha D, Holmes J, Krum H, et al. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet. 2014;384:2235–43.CrossRefPubMedGoogle Scholar
  73. 73.
    Shah M, Avgil TM, Jackevicius CA, Essebag V, Behlouli H, Pilote L. Relation of digoxin use in atrial fibrillation and the risk of all-cause mortality in patients >/=65 years of age with versus without heart failure. Am J Cardiol. 2014;114:401–6.CrossRefPubMedGoogle Scholar
  74. 74.
    Mulder BA, Van Veldhuisen DJ, Crijns HJ, et al. Digoxin in patients with permanent atrial fibrillation: data from the RACE II study. Heart Rhythm. 2014;11:1543–50.CrossRefPubMedGoogle Scholar
  75. 75.
    Nademanee K, Amnueypol M, Lee F, et al. Benefits and risks of catheter ablation in elderly patients with atrial fibrillation. Heart Rhythm. 2015;12:44–51.CrossRefPubMedGoogle Scholar
  76. 76.
    Fiala M, Wichterle D, Bulkova V, et al. A prospective evaluation of haemodynamics, functional status, and quality of life after radiofrequency catheter ablation of long-standing persistent atrial fibrillation. Europace. 2014;16:15–25.CrossRefPubMedGoogle Scholar
  77. 77.
    Fumagalli S, Tarantini F, Guarducci L, et al. Atrial fibrillation is a possible marker of frailty in hospitalized patients: results of the GIFA Study. Aging Clin Exp Res. 2010;22:129–33.CrossRefPubMedGoogle Scholar
  78. 78.
    Coyne KS, Paramore C, Grandy S, Mercader M, Reynolds M, Zimetbaum P. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health. 2006;9:348–56.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  • Stefano Fumagalli
    • 1
    Email author
  • Debbie Gabbai
    • 1
  • Luigi Padeletti
    • 2
    • 3
  • Harry J. Crijns
    • 4
  • Gregory Y. H. Lip
    • 5
  1. 1.Geriatric Intensive Care Unit, Department of Experimental and Clinical MedicineUniversity of Florence and AOU CareggiFlorenceItaly
  2. 2.Postgraduate School of Cardiology, Department of Experimental and Clinical MedicineUniversity of FlorenceFlorenceItaly
  3. 3.Cardiovascular DepartmentIRCCS MultiMedicaMilanItaly
  4. 4.Department of CardiologyMaastricht University Medical CenterMaastrichtThe Netherlands
  5. 5.City Hospital, University of Birmingham Institute of Cardiovascular SciencesBirminghamUK

Personalised recommendations